NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Tianjin Medical University Cancer Institute and Hospital
Lee's Pharmaceutical Limited
Peking University Cancer Hospital & Institute
Beijing YouAn Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Xinjiang Medical University
Sun Yat-sen University